@article{d8c1a613867b4ca7b95ce1b49509a349,
title = "Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer",
keywords = "alectinib, alk, crizotinib, nsclc, overall survival, pooled analysis, safety, ALK, NSCLC, Pooled analysis, Alectinib, CRIZOTINIB, Safety, Overall survival",
author = "S.H.I. Ou and S.M. Gadgeel and F. Barlesi and J.C.H. Yang and {De Petris}, L. and D.W. Kim and R. Govindan and A.M. Dingemans and L. Crino and H. Lena and S. Popat and J.S. Ahn and E. Dansin and E. Mitry and B. Muller and W. Bordogna and B. Balas and P.N. Morcos and A.T. Shaw",
year = "2020",
month = jan,
day = "1",
doi = "10.1016/j.lungcan.2019.10.015",
language = "English",
volume = "139",
pages = "22--27",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
}